LIKMEZ
Growthmetronidazole oral
NDAORALSUSPENSION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
LIKMEZ (metronidazole oral) is 12. First approved in 2023.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIKMEZ is an oral suspension formulation of metronidazole, a nitroimidazole antimicrobial approved in September 2023 for treatment of bacterial vaginosis. The drug works by disrupting microbial DNA through its nitroimidazole mechanism, achieving peak plasma concentrations between 0.25 and 6 hours post-administration with similar bioavailability in fed and fasted states.
Growth13.4 years to LOE
Early-stage growth product with potential to capture market share in bacterial vaginosis; smaller commercial team size typical for specialty oral antimicrobials.
Mechanism of Action
12.1 Mechanism of Action Metronidazole is a nitroimidazole antimicrobial drug [ see ] . 12.3 Pharmacokinetics Metronidazole pharmacokinetics are similar for both oral and intravenous dosage forms. The C max is dose proportional between 250 mg, 500 mg, and 2,000 mg for metronidazole oral tablets,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.